ZA200004483B - Use of retinoic acid activity inhibitors to slow down hair loss. - Google Patents
Use of retinoic acid activity inhibitors to slow down hair loss. Download PDFInfo
- Publication number
- ZA200004483B ZA200004483B ZA200004483A ZA200004483A ZA200004483B ZA 200004483 B ZA200004483 B ZA 200004483B ZA 200004483 A ZA200004483 A ZA 200004483A ZA 200004483 A ZA200004483 A ZA 200004483A ZA 200004483 B ZA200004483 B ZA 200004483B
- Authority
- ZA
- South Africa
- Prior art keywords
- acid
- composition
- substance
- activity
- inhibitor
- Prior art date
Links
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title claims description 44
- 229930002330 retinoic acid Natural products 0.000 title claims description 44
- 229960001727 tretinoin Drugs 0.000 title claims description 40
- 230000000694 effects Effects 0.000 title claims description 39
- 239000003112 inhibitor Substances 0.000 title claims description 24
- 201000004384 Alopecia Diseases 0.000 title claims description 18
- 230000003676 hair loss Effects 0.000 title claims description 12
- 208000024963 hair loss Diseases 0.000 title description 4
- 210000004209 hair Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000005711 Benzoic acid Substances 0.000 claims description 15
- 235000010233 benzoic acid Nutrition 0.000 claims description 15
- -1 3-pyridylmethyl Chemical group 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 17
- 108090000064 retinoic acid receptors Proteins 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 10
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101000883061 Chassalia parviflora Circulin-D Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000699667 Mus spretus Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101150066717 Rara gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000012412 genetic alopecia Diseases 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000006122 hypervitaminosis A Diseases 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9803978A FR2776511B1 (fr) | 1998-03-31 | 1998-03-31 | Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200004483B true ZA200004483B (en) | 2002-02-27 |
Family
ID=9524693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200004483A ZA200004483B (en) | 1998-03-31 | 2000-08-29 | Use of retinoic acid activity inhibitors to slow down hair loss. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1066017A1 (ja) |
| JP (1) | JP2002509870A (ja) |
| KR (1) | KR20010042104A (ja) |
| CN (1) | CN1298290A (ja) |
| AR (1) | AR015551A1 (ja) |
| AU (1) | AU2938899A (ja) |
| BR (1) | BR9908411A (ja) |
| CA (1) | CA2324899A1 (ja) |
| FR (1) | FR2776511B1 (ja) |
| HU (1) | HUP0102411A3 (ja) |
| IL (1) | IL137859A0 (ja) |
| NO (1) | NO20004880L (ja) |
| PL (1) | PL343004A1 (ja) |
| RU (1) | RU2193877C2 (ja) |
| WO (1) | WO1999049838A1 (ja) |
| ZA (1) | ZA200004483B (ja) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2733684B1 (fr) * | 1995-05-03 | 1997-05-30 | Cird Galderma | Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| CN1255396C (zh) * | 1996-03-18 | 2006-05-10 | 卫材株式会社 | 含有稠环的羧酸衍生物 |
-
1998
- 1998-03-31 FR FR9803978A patent/FR2776511B1/fr not_active Expired - Fee Related
-
1999
- 1999-03-24 JP JP2000540805A patent/JP2002509870A/ja active Pending
- 1999-03-24 PL PL99343004A patent/PL343004A1/xx not_active Application Discontinuation
- 1999-03-24 KR KR1020007010470A patent/KR20010042104A/ko not_active Application Discontinuation
- 1999-03-24 RU RU2000127111/14A patent/RU2193877C2/ru active
- 1999-03-24 BR BR9908411-2A patent/BR9908411A/pt not_active IP Right Cessation
- 1999-03-24 AU AU29388/99A patent/AU2938899A/en not_active Abandoned
- 1999-03-24 CA CA002324899A patent/CA2324899A1/fr not_active Abandoned
- 1999-03-24 CN CN99804411A patent/CN1298290A/zh active Pending
- 1999-03-24 EP EP99910423A patent/EP1066017A1/fr not_active Withdrawn
- 1999-03-24 IL IL13785999A patent/IL137859A0/xx unknown
- 1999-03-24 WO PCT/FR1999/000687 patent/WO1999049838A1/fr not_active Application Discontinuation
- 1999-03-24 HU HU0102411A patent/HUP0102411A3/hu unknown
- 1999-03-30 AR ARP990101412A patent/AR015551A1/es unknown
-
2000
- 2000-08-29 ZA ZA200004483A patent/ZA200004483B/en unknown
- 2000-09-28 NO NO20004880A patent/NO20004880L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102411A2 (hu) | 2001-11-28 |
| KR20010042104A (ko) | 2001-05-25 |
| CN1298290A (zh) | 2001-06-06 |
| JP2002509870A (ja) | 2002-04-02 |
| BR9908411A (pt) | 2000-12-05 |
| CA2324899A1 (fr) | 1999-10-07 |
| PL343004A1 (en) | 2001-07-30 |
| NO20004880L (no) | 2000-11-30 |
| AR015551A1 (es) | 2001-05-02 |
| AU2938899A (en) | 1999-10-18 |
| HUP0102411A3 (en) | 2002-12-28 |
| IL137859A0 (en) | 2001-10-31 |
| RU2193877C2 (ru) | 2002-12-10 |
| WO1999049838A1 (fr) | 1999-10-07 |
| EP1066017A1 (fr) | 2001-01-10 |
| FR2776511B1 (fr) | 2001-05-11 |
| FR2776511A1 (fr) | 1999-10-01 |
| NO20004880D0 (no) | 2000-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8288366B2 (en) | Formulation for hair growth | |
| JP3004718B2 (ja) | カリウムチャネルオープナーおよび５α―レダクターゼ抑制剤を用いる育毛刺激 | |
| PL186821B1 (pl) | Zastosowanie ligandu antagonistycznego RAR-gama i/lub ligandu agonistycznego RAR-alfa jako inhibitorów apoptozy | |
| AU2013343232A1 (en) | Dermal compositions containing unnatural hygroscopic amino acids | |
| DE60103374D1 (de) | Zweiteilige kosmetische zusammensetzung enthaltend ein in höheren konzentrationen hautreizendes und ein dazu inkompatibles mittel in der ersten respektive zweiten zusammensetzung | |
| EP0817625B1 (en) | Compositions for treatment of photodamaged skin comprising an rar-alpha antagonist and a multi-selective retinoid | |
| CA2241244C (fr) | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v. | |
| US20020052416A1 (en) | Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs | |
| US5827500A (en) | Process for identifying RAR-receptor-antagonist compounds | |
| ZA200004483B (en) | Use of retinoic acid activity inhibitors to slow down hair loss. | |
| US8790626B2 (en) | Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore | |
| US20080200477A1 (en) | Retinoid-Containing Compositions Having Reduced Irritation Effect | |
| CA2625381C (en) | Compositions containing retinoid and beta-aminoisobutyic acid derivatives | |
| US5696104A (en) | Process for identifying RXR-receptor-agonist compounds | |
| MXPA00008971A (en) | Use of retinoic acid activity inhibitors to slow down hair loss | |
| JP2003518034A (ja) | 化粧品又は製薬組成物におけるｐｐａｒ型受容体活性化剤としての芳香族多環式化合物の使用 | |
| Marks et al. | Medical Treatments for Androgenetic Alopecia | |
| CA2307298C (en) | Skin care composition comprising dipotassium glycyrrhizinate, tretinoin and hydroquinone |